Given that PD-L1 blockade by avelumab in combination with axitinib, a vascular endothelial growth factor receptor (VEGFR) inhibitor, is effective as a first-line treatment for advanced ccRCC [152], PD-L1 may be a potential target molecule for NIR-PIT, especially in ccRCC. Here, KDR is linked to nonpapillary renal cell carcinoma.